Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28711
Title: | Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting | Authors: | Albrecht, Philipp Bjorna, Ingrid Kristine Brassat, David Farrell, Rachel FEYS, Peter Hobart, Jeremy Hupperts, Raymond Linnebank, Michael Magdic, Jozef Oreja-Guevara, Celia Pozzilli, Carlo Salgado, Antonio Vasco Ziemssen, Tjalf |
Issue Date: | 2018 | Publisher: | SAGE PUBLICATIONS LTD | Source: | Therapeutic Advances in Neurological Disorders, 11, p. 1-8 | Abstract: | Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and retreatment, and stopping criteria. This article summarizes the experts' opinions on how PRfampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability. | Notes: | [Albrecht, Philipp] Heinrich Heine Univ, Med Fac, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany. [Bjorna, Ingrid Kristine] Vestre Viken, Drammen Sykehus, Neurol Dept, Drammen, Germany. [Brassat, David] Univ Toulouse III, CHU Toulouse, SEP, Ctr Resource & Competence, Toulouse, France. [Brassat, David] Univ Toulouse III, UMR1043, Toulouse, France. [Farrell, Rachel] UCL Inst Neurol, Dept Neuroinflammat, London, England. [Farrell, Rachel] UCLH NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England. [Feys, Peter] Hasselt Univ, Fac Rehabil Sci, BIOMED, REVAL, Hasselt, Belgium. [Hobart, Jeremy] Plymouth Univ Peninsula, Sch Med, Dept Clin Trials & Hlth Res Translat & Stratified, Plymouth, Devon, England. [Hobart, Jeremy] Plymouth Univ Peninsula, Sch Dent, Dept Clin Trials & Hlth Res Translat & Stratified, Plymouth, Devon, England. [Hupperts, Raymond] Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands. [Linnebank, Michael] Helios Clin Hagen Ambrock, Dept Neurol, Hagen, Germany. [Magdic, Jozef] Univ Med Ctr Maribor, Dept Neurol, Maribor, Slovenia. [Oreja-Guevara, Celia] Univ Complutense Madrid, Dept Med, Hosp Clin San Carlos, Neurol, Madrid, Spain. [Oreja-Guevara, Celia] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain. [Pozzilli, Carlo] Univ Roma La Sapienza, Dept Neurol, Rome, Italy. [Salgado, Antonio Vasco] Hosp Fernando Fonseca, Serv Neurol, Amadora, Portugal. [Ziemssen, Tjalf] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, MS Ctr Dresden, Ctr Clin Neurosci,Dept Neurol, Dresden, Germany. | Keywords: | multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability;multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability | Document URI: | http://hdl.handle.net/1942/28711 | ISSN: | 1756-2856 | e-ISSN: | 1756-2864 | DOI: | 10.1177/1756286418803248 | ISI #: | 000455655900001 | Rights: | The Author(s), 2018. Article reuse guidelines: sagepub.com/journalspermissions Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
albrecht 1.pdf | Published version | 102.07 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
2
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
8
checked on Jul 26, 2024
Page view(s)
166
checked on Aug 31, 2022
Download(s)
204
checked on Aug 31, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.